Osteoarthritis - StatPearls - NCBI Bookshelf - NIH

Trust note

What this source is and what it can support

Summary

Clinical reference describing epidemiology and practical diagnostic points in OA, including the mismatch that can exist between radiographs and symptoms. Helpful for judging what counts as meaningful benefit.

Why this source matters

The StatPearls osteoarthritis overview is a useful clinical reference from NCBI Bookshelf / the National Library of Medicine. It is not a 15-PGDH paper, but it gives a practical reminder that osteoarthritis is a symptom-driven disease and that imaging changes do not always track with pain or function.

This source is rated medium quality because it is a secondary clinical summary rather than a primary study or formal guideline. It is still credible for general orientation, but it should be used as supporting context rather than as the main proof for a new therapy claim.

What it supports is the idea that a future 15-PGDH therapy would need to show real patient benefit, not just a shift in biomarkers or radiographs. What it does not prove is whether the target works, whether it reaches joint tissue, or whether it can change the course of osteoarthritis.

This source is largely independent from the WHO fact sheet and the guideline review in this set, although it tells the same broad story from a clinical-reference angle. That agreement helps with confidence on the background framing, but the source still does not answer the target-specific question by itself.

Author, publisher, and institution context: StatPearls is a medical reference published through NCBI Bookshelf and associated with the National Library of Medicine. It is written by clinicians for educational use, which gives it practical value but also means it is a summary rather than a trial report.

What to look at in the source

Relevant parts

• Epidemiology section on global prevalence and disability burden
• Statements noting that radiographic osteoarthritis does not always match symptoms

Key findings

• OA is common and disabling.
• Radiographic OA does not always match symptoms.
• Clinical benefit should be judged by patient outcomes, not imaging alone.

Notable wording from the source

Go to: ## Epidemiology Osteoarthritis affects about 3.3 to 3.6% of the population globally.

It causes moderate to severe disability in 43 million people, making it the 11th most debilitating disease worldwide.

How much weight to give it

For most readers, the main question is not how this source is classified internally. It is whether this source deserves real weight in the answer. This one is best treated as a medium quality expert consensus source.

Used to reinforce the point that symptom benefit matters more than lab or imaging movement alone. It does not establish that 15-PGDH is effective, safe, or close to use in patients.

The source is trustworthy enough for broad clinical orientation because it is tied to an established medical reference platform and written by health professionals. It should be treated cautiously for any mechanistic or therapeutic claim about 15-PGDH because it does not test that target.

This clinical reference was stored because it adds practical medical context, especially the distinction between imaging findings and symptoms. That is useful when evaluating whether a future 15-PGDH signal would be clinically meaningful or just a biomarker shift.

Limits to keep in mind

• Secondary summary, not primary evidence.
• Not specific to 15-PGDH or any experimental therapy.